Cardax

Cardax FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Cardax (CDXI) as of Oct 20, 2026 is 35.44 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 69.17 % — a change of -48.77% (lower).

FCF Conversion

35.44 %

YoY

-48.77%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Cardax is 2020 35.44 % . FCF Conversion Rate (FCF/EBITDA) of Cardax was 2019 69.17 % . It decreases by -48.77% lower compared to the previous year.

The Cardax FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2015
35.37 USD
Jan 1, 2016
70.46 USD
Jan 1, 2017
104.81 USD
Jan 1, 2018
79.53 USD
Jan 1, 2019
69.17 USD
Jan 1, 2020
35.44 USD
The Cardax FCF Conversion history
YEARFCF ConversionYoY
35.44 %-48.77%
69.17 %-13.03%
79.53 %-24.12%
104.81 %+48.74%
70.46 %+99.19%
35.37 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cardax Stock analysis

What does Cardax do? Cardax Inc, a development stage biopharmaceutical company based in Honolulu, Hawaii, focuses on developing pharmaceuticals for chronic diseases driven by inflammation. The company has 10 full-time employees and went public via an IPO on January 30, 2012. Cardax is currently developing two pre-clinical pharmaceutical candidates: CDX-101 and CDX-301. CDX-101 is a proprietary astaxanthin prodrug designed to deliver astaxanthin to the bloodstream following oral administration. Astaxanthin is a naturally occurring molecule known for its anti-inflammatory properties, supporting cardiovascular health, metabolic health, liver health, joint health, and longevity. CDX-301 is a pharmaceutical candidate for macular degeneration, utilizing zeaxanthin, which accumulates in the human eye through a retinal receptor to protect against blue light, oxidative damage, and inflammation associated with macular degeneration. The company's headquarters are located in Honolulu, and it operates within the Health Care sector, specifically in the Pharmaceuticals industry. Cardax Inc's website is https://cardaxpharma.com/. The company is seeking to monetize its pre-clinical candidates, CDX-101 and CDX-301, as it advances its development pipeline. No additional details about the company's financials, specific acquisition history, or other product names are provided in the available information. Cardax is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cardax stock

FCF Conversion Rate (FCF/EBITDA) of Cardax is 35.44 % in 2020.

FCF Conversion Rate (FCF/EBITDA) of Cardax changed from 69.17 % to 35.44 %, representing a -48.77% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Cardax since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Cardax with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Cardax

All Key Metrics — Cardax